ArticleEJHaem2025
Ruxolitinib and Hydroxycarbamide Are the Most Efficient Drugs to Reduce Aquagenic Pruritus Intensity in a Real-Word Cohort of Patients With Myeloproliferative Neoplasms.
Article in EJHaem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02897297 (Observatoire Brestois Des Néoplasies Myéloprolifératives), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Observatoire Brestois Des Néoplasies Myéloprolifératives
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Aquagenic pruritus (AP) is a common and distressing symptom in myeloproliferative neoplasm (MPN) patients. Methods: This study assessed cytoreductive therapy effectiveness using data from 489 patients in the OBENE Observatory (NCT02897297). AP severity was tracked regularly after diagnosis. Results: Ruxolitinib and hydroxycarbamide reduced AP by 52.9% and 60.7%, respectively, but 61.4% still experienced persistent symptoms. Anagrelide and pegylated interferon were less effective and occasionally worsened AP. No correlation was found between full hematological response and symptom relief. Conclusion: Despite treatment, AP remains prevalent, highlighting the need for targeted symptom management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.